Varicella Zoster (HHV-3) Infections - Pipeline Review, H2 2016
Summary
Global Markets Direct’s, ‘Varicella Zoster (HHV-3) Infections - Pipeline Review, H2 2016’, provides an overview of the Varicella Zoster (HHV-3) Infections pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Varicella Zoster (HHV-3) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Varicella Zoster (HHV-3) Infections and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
Certain sections in the report may be removed or altered based on the availability and relevance of data.Scope- The report provides a snapshot of the global therapeutic landscape of Varicella Zoster (HHV-3) Infections
- The report reviews pipeline therapeutics for Varicella Zoster (HHV-3) Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Varicella Zoster (HHV-3) Infections therapeutics and enlists all their major and minor projects
- The report assesses Varicella Zoster (HHV-3) Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Varicella Zoster (HHV-3) Infections
Reasons to buy- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Varicella Zoster (HHV-3) Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Varicella Zoster (HHV-3) Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Introduction
- Global Markets Direct Report Coverage
- Varicella Zoster (HHV-3) Infections Overview
- Therapeutics Development
- Pipeline Products for Varicella Zoster (HHV-3) Infections - Overview
- Pipeline Products for Varicella Zoster (HHV-3) Infections - Comparative Analysis
- Varicella Zoster (HHV-3) Infections - Therapeutics under Development by Companies
- Varicella Zoster (HHV-3) Infections - Therapeutics under Investigation by Universities/Institutes
- Varicella Zoster (HHV-3) Infections - Pipeline Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Unknown Stage Products
- Varicella Zoster (HHV-3) Infections - Products under Development by Companies
- Varicella Zoster (HHV-3) Infections - Products under Investigation by Universities/Institutes
- Varicella Zoster (HHV-3) Infections - Companies Involved in Therapeutics Development
- Astellas Pharma Inc.
- Beijing Minhai Biotechnology Co., Ltd
- Beijing Tiantan Biological Products Co., Ltd.
- ContraVir Pharmaceuticals, Inc.
- Epiphany Biosciences, Inc.
- Foamix Pharmaceuticals Ltd.
- GeneOne Life Science, Inc.
- GlaxoSmithKline Plc
- Green Cross Corporation
- Merck & Co., Inc.
- N & N Pharmaceuticals Inc.
- NAL Pharmaceuticals Ltd.
- NanoViricides, Inc.
- ReceptoPharm, Inc.
- Sinovac Biotech Ltd.
- SK Chemicals Co., Ltd.
- TSRL, Inc.
- XBiotech Inc
- Zydus Cadila Healthcare Limited
- Varicella Zoster (HHV-3) Infections - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- (measles + mumps + rubella + varicella) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- (measles + rubella + varicella) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- acyclovir - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- amenamevir - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- chickenpox vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- FV-100 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- GLS-5100 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- GSK-1437173A - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- herpes zoster vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- HHV-3 vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- measles + mumps + rubella + varicella vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- MG-1111 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Monoclonal Antibody for Shingles - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- NAL-3221 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- NAL-3223 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- NBP-608 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- NN-001 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- RKP-00156 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- RPI-78M - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- sattabacin - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecule for Shingles - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- TSR-087 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- V-212 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- valomaciclovir stearate - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- varicella zoster vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Varicella Zoster (HHV-3) Infections - Dormant Projects
- Varicella Zoster (HHV-3) Infections - Discontinued Products
- Varicella Zoster (HHV-3) Infections - Product Development Milestones
- Featured News & Press Releases
- Sep 14, 2016: GSKs candidate shingles vaccine shows high efficacy against shingles and its complications in adults aged 70 years and over in phase III study published in NEJM
- Jun 16, 2016: ContraVir Pharmaceuticals Expands Patient Enrollment Criteria for Ongoing Phase 3 Clinical Study of FV-100 for Treating Shingles
- Apr 20, 2016: N&N Pharmaceuticals Commences Clinical Trials on its Novel Antiviral Drug
- Mar 03, 2016: ContraVir Pharmaceuticals Reports Positive Results Confirming the Safety of its Shingles Candidate FV-100 in a Drug-Drug Interaction Study
- Oct 27, 2015: GSK’s candidate shingles vaccine demonstrates 90% efficacy against shingles in people 70 years of age and over
- Oct 26, 2015: Sinovac Receives Clinical Trial Approval for Varicella Vaccine Candidate
- Sep 08, 2015: Clinical trial for Cardiff’s shingles treatment
- Aug 03, 2015: ContraVir Pharmaceuticals Enrolls First Patient in Pivotal Phase 3 Study of FV-100 for Treatment of Shingles and Shingles-Associated Pain
- Jun 09, 2015: ContraVir Pharmaceuticals Selects ImageIQ as Imaging CRO for Phase III Clinical Trial
- Apr 28, 2015: GSK candidate vaccine for the prevention of shingles demonstrates overall efficacy of 97.2% which does not diminish in the age groups studied
- Mar 09, 2015: ContraVir Pharmaceuticals to Initiate Pivotal Phase 3 Study of FV-100 for Prevention of Shingles-Associated PHN
- Dec 18, 2014: Pivotal phase III study of GSK shingles candidate vaccine meets its primary endpoint
- Dec 18, 2014: Positive Outcome of Phase 3 Study of GSK Shingles Vaccine Containing Agenus Adjuvant
- Dec 09, 2014: ContraVir Pharmaceuticals Initiates Pharmacokinetic Study of Lead Antiviral FV-100 for Treating Shingles
- Oct 16, 2014: ContraVir Pharmaceuticals Selects Pharmaceutical Product Development to Manage Phase 2b Study of Lead Antiviral FV-100 for Treating Shingles
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products under Development for Varicella Zoster (HHV-3) Infections, H2 2016
- Number of Products under Development for Varicella Zoster (HHV-3) Infections - Comparative Analysis, H2 2016
- Number of Products under Development by Companies, H2 2016
- Number of Products under Investigation by Universities/Institutes, H2 2016
- Comparative Analysis by Late Stage Development, H2 2016
- Comparative Analysis by Clinical Stage Development, H2 2016
- Comparative Analysis by Early Stage Development, H2 2016
- Comparative Analysis by Unknown Stage Development, H2 2016
- Products under Development by Companies, H2 2016
- Products under Investigation by Universities/Institutes, H2 2016
- Varicella Zoster (HHV-3) Infections - Pipeline by Astellas Pharma Inc., H2 2016
- Varicella Zoster (HHV-3) Infections - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2016
- Varicella Zoster (HHV-3) Infections - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H2 2016
- Varicella Zoster (HHV-3) Infections - Pipeline by ContraVir Pharmaceuticals, Inc., H2 2016
- aricella Zoster (HHV-3) Infections - Pipeline by Epiphany Biosciences, Inc., H2 2016
- Varicella Zoster (HHV-3) Infections - Pipeline by Foamix Pharmaceuticals Ltd., H2 2016
- Varicella Zoster (HHV-3) Infections - Pipeline by GeneOne Life Science, Inc., H2 2016
- Varicella Zoster (HHV-3) Infections - Pipeline by GlaxoSmithKline Plc, H2 2016
- Varicella Zoster (HHV-3) Infections - Pipeline by Green Cross Corporation, H2 2016
- Varicella Zoster (HHV-3) Infections - Pipeline by Merck & Co., Inc., H2 2016
- Varicella Zoster (HHV-3) Infections - Pipeline by N & N Pharmaceuticals Inc., H2 2016
- Varicella Zoster (HHV-3) Infections - Pipeline by NAL Pharmaceuticals Ltd., H2 2016
- Varicella Zoster (HHV-3) Infections - Pipeline by NanoViricides, Inc., H2 2016
- Varicella Zoster (HHV-3) Infections - Pipeline by ReceptoPharm, Inc., H2 2016
- Varicella Zoster (HHV-3) Infections - Pipeline by Sinovac Biotech Ltd., H2 2016
- Varicella Zoster (HHV-3) Infections - Pipeline by SK Chemicals Co., Ltd., H2 2016
- Varicella Zoster (HHV-3) Infections - Pipeline by TSRL, Inc., H2 2016
- Varicella Zoster (HHV-3) Infections - Pipeline by XBiotech Inc, H2 2016
- Varicella Zoster (HHV-3) Infections - Pipeline by Zydus Cadila Healthcare Limited, H2 2016
- Assessment by Monotherapy Products, H2 2016
- Assessment by Combination Products, H2 2016
- Number of Products by Stage and Target, H2 2016
- Number of Products by Stage and Mechanism of Action, H2 2016
- Number of Products by Stage and Route of Administration, H2 2016
- Number of Products by Stage and Molecule Type, H2 2016
- Varicella Zoster (HHV-3) Infections - Dormant Projects, H2 2016
- Varicella Zoster (HHV-3) Infections - Discontinued Products, H2 2016
- List of Figures
- Number of Products under Development for Varicella Zoster (HHV-3) Infections, H2 2016
- Number of Products under Development for Varicella Zoster (HHV-3) Infections - Comparative Analysis, H2 2016
- Number of Products under Development by Companies, H2 2016
- Comparative Analysis by Clinical Stage Development, H2 2016
- Comparative Analysis by Early Stage Products, H2 2016
- Assessment by Monotherapy Products, H2 2016
- Assessment by Combination Products, H2 2016
- Number of Products by Targets, H2 2016
- Number of Products by Stage and Targets, H2 2016
- Number of Products by Mechanism of Actions, H2 2016
- Number of Products by Stage and Mechanism of Actions, H2 2016
- Number of Products by Routes of Administration, H2 2016
- Number of Products by Stage and Routes of Administration, H2 2016
- Number of Products by Molecule Types, H2 2016
- Number of Products by Stage and Molecule Types, H2 2016